The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the α-Subunit of Glycoprotein Hormones
Abstract
Chromogranin A (CgA) is gaining acceptance as a serum marker of neuroendocrine tumors. Its specificity in differentiating between neuroendocrine and nonneuroendocrine tumors, its sensitivity to detect small tumors, and its clinical value, compared with other neuroendocrine markers, have not clearly been defined, however. The objectives of this study were to evaluate the clinical usefulness of CgA as neuroendocrine serum marker. Serum levels of CgA, neuron-specific enolase (NSE), and the alpha-subunit of glycoprotein hormones (alpha-SU) were determined in 211 patients with neuroendocrine tumors and 180 control subjects with nonendocrine tumors. The concentrations of CgA, NSE, and alpha-SU were elevated in 50%, 43%, and 24% of patients with neuroendocrine tumors, respectively. Serum CgA was most frequently increased in subjects with gastrinomas (100%), pheochromocytomas (89%), carcinoid tumors (80%), nonfunctioning tumors of the endocrine pancreas (69%), and medullary thyroid carcinomas (50%). The highest levels were observed in subjects with carcinoid tumors. NSE was most frequently elevated in patients with small cell lung carcinoma (74%), and alpha-SU was most frequently elevated in patients with carcinoid tumors (39%). Most subjects with elevated alpha-SU levels also had elevated CgA concentrations. A significant positive relationship was demonstrated between the tumor load and serum CgA levels (P < 0.01, by chi 2 test). Elevated concentrations of CgA, NSE, and alpha-SU were present in, respectively, 7%, 35%, and 15% of control subjects. Markedly elevated serum levels of CgA, exceeding 300 micrograms/L, were observed in only 2% of control patients (n = 3) compared to 40% of patients with neuroendocrine tumors (n = 76). We conclude that CgA is the best general neuroendocrine serum marker available. It has the highest specificity for the detection of neuroendocrine tumors compared to the other neuroendocrine markers, NSE and alpha-SU. Elevated levels are strongly correlated with tumor volume; therefore, small tumors may go undetected. Although its specificity cannot compete with that of the specific hormonal secretion products of most neuroendocrine tumors, it can have useful clinical applications in subjects with neuroendocrine tumors for whom either no marker is available or the marker is inconvenient for routine clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells
SCHMECHEL, D., MARANGOS, P. J., & BRIGHTMAN, M. (1978) · Nature · doi:10.1038/276834a0 · Cited by 723
Somatostatin-Receptor Imaging in the Localization of Endocrine Tumors
Lamberts, S. W. J., Barker, W. H., Reubi, J.-C., & Krenning, E. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231805 · Cited by 532
Self-citationSecretion of Chromogranin A by Peptide-Producing Endocrine Neoplasms
O'Connor, D. T., & Deftos, L. J. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605013141803 · Cited by 477
Di Sant'Agnese, P. A. (1992) · Cancer · doi:10.1002/1097-0142(19920701)70:1+<254::aid-cncr2820701312>3.0.co;2-e · Cited by 387
Chromogranin A: Its Role in Endocrine Function and as an Endocrine and Neuroendocrine Tumor Marker*
DEFTOS, L. J. (1991) · Endocrine Reviews · doi:10.1210/edrv-12-2-181 · Cited by 261
O'Connor, D. T., & Bernstein, K. N. (1984) · New England Journal of Medicine · doi:10.1056/nejm198409203111204 · Cited by 228
O'Connor, D. T., Pandlan, M. R., Carlton, E., Cervenka, J. H., & Hslao, R. J. (1989) · Clinical Chemistry · doi:10.1093/clinchem/35.8.1631 · Cited by 168
Elevated Plasma Chromogranin-A Concentrations in Prostatic Carcinoma
Kadmon, D., Thompson, T. C., Lynch, G. R., & Scardino, P. T. (1991) · Journal of Urology · doi:10.1016/s0022-5347(17)37793-5 · Cited by 165
Neuroendocrine Pancreatic Tumors Clinical Findings in a prospective study of 84 patients
Eriksson, B. K., Ouberg, K., & Skogseid, B. M. (1989) · Acta Oncologica · doi:10.3109/02841868909111209 · Cited by 128
Weiler, R., Fischer‐Colbrie, R., Schmid, K. W., Feichtinger, H. G., Bussolati, G., Grimelius, L., KRISCH, K., Kerl, H., OʼConnor, D., & Winkler, H. J. S. (1988) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198811000-00008 · Cited by 105
Hormone-Negative, Chromogranin a-Positive Endocrine Tumors
Sobol, R. E., Memoli, V. A., & Deftos, L. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902163200707 · Cited by 97
Elevated Serum Chromogranin A Concentrations in Small-Cell Lung Carcinoma
Sobol, R. E., O'CONNOR, D. T., ADDISON, J., SUCHOCKI, K., Royston, I., & DEFTOS, L. J. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-5-698 · Cited by 96
Hsiao, R. J., Parmer, R. J., Barbosa, J. A., O’Connor, D. T., & Neumann, H. P. H. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90526-j · Cited by 87
Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours
Sundaresan, V., Reeve, J. G., Stenning, S. P., Stewart, S., & Bleehen, N. M. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.301 · Cited by 85
Endocrine cells in colorectal adenocarcinomas: Incidence, hormone profile and prognostic relevance
A, A. P. D. B., Wiggers, T., Beek, C. J., Volovics, A., MEYENFELDT, M. F. V., Arends, J. W., & Bosman, F. T. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540510 · Cited by 85
Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome
D’Adda, T., Corleto, V. D., Pilato, F. P., Baggi, M. T., Robutti, F., Fave, G. D., & Bordi, C. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)91224-t · Cited by 84
Deftos, L. J., Nakada, S. Y., Burton, D. W., di Sant'Agnese, P. A., Cockett, A. T. �., & Abrahamsson, P.-A. (1996) · Urology · doi:10.1016/s0090-4295(96)00089-1 · Cited by 82
Eriksson, B. K., Arnberg, H., Öberg, K., Hellman, U., Lundqvist, G., Wernstedt, C., & Wilander, E. (1990) · European Journal of Endocrinology · doi:10.1530/acta.0.1220145 · Cited by 75
Lloyd, R. V., Iacangelo, A. L., Eiden, L. E., Cano, M., Jin, L. G., & Grimes, M. L. (1989) · PubMed · Cited by 74
Pour, P. M., Permert, J., Mogaki, M., Fujii, H., & Kazakoff, K. R. (1993) · American Journal of Clinical Pathology · doi:10.1093/ajcp/100.3.223 · Cited by 68
Source of Plasma Chromogranin A Elevation in Gastrinoma Patients
Stabile, B. E. (1990) · Archives of Surgery · doi:10.1001/archsurg.1990.01410160037007 · Cited by 59
Scopsi, L., Andreola, S. A., Pilotti, S., Testori, A., Baldini, M. T., Leoni, F., Lombardi, L., Hutton, J. C., Shimizu, F., Rosa, P., et al. (1992) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199206000-00004 · Cited by 52
Nobels, F. R. E., Kwekkeboom, D. J., Coopmans, W., Hoekstra, R., de Herder, W. W., Bouillon, R., & Lamberts, S. W. J. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.3.7690365 · Cited by 42
Self-citationHuman Pituitary Tumors Secrete Chromogranin-A*
Deftos, L. J., O’Connor, D. T., Wilson, C. B., & FITZGERALD, P. A. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-5-869 · Cited by 39
Serum chromogranin A in the differential diagnosis of Cushing's syndrome
Nobels, F. R. E., de Herder, W. W., Kwekkeboom, D. J., Coopmans, W., Mulder, A., Bouillon, R., & Lamberts, S. W. J. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1310589 · Cited by 31
Self-citation
Cited by
Current Status of Gastrointestinal Carcinoids
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., & Shapiro, M. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.038 · Cited by 848
Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
Metz, D. C., & Jensen, R. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.047 · Cited by 816
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects
Isgrò, M. A., Bottoni, P., & Scatena, R. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-017-7215-0_9 · Cited by 575
Endocrine tumours of the pancreas
Öberg, K., & Eriksson, B. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.06.002 · Cited by 543
Metadata
- Authors
- Nobels, F. R. E., Kwekkeboom, D. J., Coopmans, W., Schoenmakers, C. H. H., Lindemans, J., De Herder, W. W., Krenning, E. P., Bouillon, R., & Lamberts, S. W. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-08
- Volume
- 82
- Issue
- 8
- Pages
- 2622-2628
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2150004274
- Cited by
- 352
- References
- 25
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.